- Email: [email protected]
Treatment of seizure disorders and pharmaceutical compositions useful therein
iv
New Patents
said fraction and the pharmaceutical compositions containing said fraction. The characteristics are notably the following: it is substantially free of the inhibitors having molecular weights lower than 30,000; it is lyophilizable without loss of biological properties; it exhibits the biological activities in the form of a solution having a pH of at least 7; it stimulates H-thymidin incorporation by bonemarrow cells in vitro and in vivo; the water soluble fraction is capable of controlling the immune reactions of a host against allogenic cells or tissue.
4540582 TREATMENT OF SEIZURE DISORDERS AND PHARMACEUTICAL COMPOSITIONS USEFUL THEREIN Nikolaus Seiler, Shakir Sarhan, Strasbourg, France assigned to Merrell Dow Pharmaceuticals Inc Glycine, sarcosine, or N,N-dimethylglycine exerts a synergistic effect upon gamma-vinyl GABA for the treatment of seizure disorders, in particular epilepsy.
4540602 PROCESS FOR THE PREPARATION OF ACTIVATED PHARMACEUTICAL COMPOSITIONS Shimesu Motoyama, Satashi Sato, Seiichi Umeda, Hirotsune Yasumi, Emiko Suto, Yuko Takasaka, Takuichi Tsujino, Asaka, Japan assigned to Freund Industry Company Limited Disclosed is a process for the preparation of an activated pharmaceutical composition containing a solid drug that is scarcely soluble in water, the pharmaceutical composition being characterized in that, when it is administered orally, the drug is readily absorbed to attain its high blood concentration quickly. This process is carried out by providing a solid drug that is scarcely soluble in water, dispersing the drug in water in the presence of a water-soluble highmolecular substance to form a disperse system containing the drug in the form of finely divided particles substantially not greater than 10 mu in
diameter, and then removing the water from the disperse system.
4540662 SEMISYNTHETIC MACROLIDIC ANTIBIOTICS, INTERMEDIATE C O M P O U N D S FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS CONTAINING C O M P O U N D S FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Luciano Toscano, Leonard M Cappelletti, Milan, NY, Italy assigned to Pierrel S p A From the fermentation carried, out with mutants blocked in the synthesis respectively of erythromycin and of oleandomycin, namely Streptomyces erythreus ATCC 31772 and Streptomyces antibioticus ATCC 31771, using as the substrate a derivative of erythronolide A, namely (8S)-B-fluoroerythronolide A, a derivative of erythronolide B, namely (8S)-Bfluoroerythronolide B, or a derivative of 3-0mycarosyl-erythronolide B, namely 3-0mycarosyl-(8S)-ftuoroerythronolide B, the corresponding (8S)-8-fluoro derivatives of the erythromycins A,B, C and D, as well as 3-0oleandrosyl-5-desosaminyl-(8S)-8fluoroerythronolide A and 3-O-oleandrosyl-5O-desosaminyl-(8S)-8-fiuoroerythronolide B, all belonging to the class of the marcolide antibiotics are obtained. The preparation of the aforesaid substrate comprises the convention of erythronolide A, erythronolide B or 3-0mycarosyl-erythronolide B into the corresponding hemiacetal, the reaction of the latter with a compound capable of generating electrophlic fluorine and the opening of the resulting acetal with aqueous acid.
4540682 PHARMACEUTICAL PEPTIDES, PREPARATION, USE AND INTERMEDIATES George W Hardy, Lawrence Lowe, Terence Smith, Biggin Hill, United Kingdom assigned to Burroughs Wellcome Co
New Patents
said fraction and the pharmaceutical compositions containing said fraction. The characteristics are notably the following: it is substantially free of the inhibitors having molecular weights lower than 30,000; it is lyophilizable without loss of biological properties; it exhibits the biological activities in the form of a solution having a pH of at least 7; it stimulates H-thymidin incorporation by bonemarrow cells in vitro and in vivo; the water soluble fraction is capable of controlling the immune reactions of a host against allogenic cells or tissue.
4540582 TREATMENT OF SEIZURE DISORDERS AND PHARMACEUTICAL COMPOSITIONS USEFUL THEREIN Nikolaus Seiler, Shakir Sarhan, Strasbourg, France assigned to Merrell Dow Pharmaceuticals Inc Glycine, sarcosine, or N,N-dimethylglycine exerts a synergistic effect upon gamma-vinyl GABA for the treatment of seizure disorders, in particular epilepsy.
4540602 PROCESS FOR THE PREPARATION OF ACTIVATED PHARMACEUTICAL COMPOSITIONS Shimesu Motoyama, Satashi Sato, Seiichi Umeda, Hirotsune Yasumi, Emiko Suto, Yuko Takasaka, Takuichi Tsujino, Asaka, Japan assigned to Freund Industry Company Limited Disclosed is a process for the preparation of an activated pharmaceutical composition containing a solid drug that is scarcely soluble in water, the pharmaceutical composition being characterized in that, when it is administered orally, the drug is readily absorbed to attain its high blood concentration quickly. This process is carried out by providing a solid drug that is scarcely soluble in water, dispersing the drug in water in the presence of a water-soluble highmolecular substance to form a disperse system containing the drug in the form of finely divided particles substantially not greater than 10 mu in
diameter, and then removing the water from the disperse system.
4540662 SEMISYNTHETIC MACROLIDIC ANTIBIOTICS, INTERMEDIATE C O M P O U N D S FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS CONTAINING C O M P O U N D S FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Luciano Toscano, Leonard M Cappelletti, Milan, NY, Italy assigned to Pierrel S p A From the fermentation carried, out with mutants blocked in the synthesis respectively of erythromycin and of oleandomycin, namely Streptomyces erythreus ATCC 31772 and Streptomyces antibioticus ATCC 31771, using as the substrate a derivative of erythronolide A, namely (8S)-B-fluoroerythronolide A, a derivative of erythronolide B, namely (8S)-Bfluoroerythronolide B, or a derivative of 3-0mycarosyl-erythronolide B, namely 3-0mycarosyl-(8S)-ftuoroerythronolide B, the corresponding (8S)-8-fluoro derivatives of the erythromycins A,B, C and D, as well as 3-0oleandrosyl-5-desosaminyl-(8S)-8fluoroerythronolide A and 3-O-oleandrosyl-5O-desosaminyl-(8S)-8-fiuoroerythronolide B, all belonging to the class of the marcolide antibiotics are obtained. The preparation of the aforesaid substrate comprises the convention of erythronolide A, erythronolide B or 3-0mycarosyl-erythronolide B into the corresponding hemiacetal, the reaction of the latter with a compound capable of generating electrophlic fluorine and the opening of the resulting acetal with aqueous acid.
4540682 PHARMACEUTICAL PEPTIDES, PREPARATION, USE AND INTERMEDIATES George W Hardy, Lawrence Lowe, Terence Smith, Biggin Hill, United Kingdom assigned to Burroughs Wellcome Co